|Articles|March 10, 2023
- Pharmaceutical Executive: March 2023
- Volume 43
- Issue 3
Pharmaceutical Executive, March 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 3 years ago
Navigating Disruption in the Metapharma Eraabout 3 years ago
Biopharma M&A: Year in Review, Ripples Aheadabout 3 years ago
Balancing Pharma Hiring Practices in Good Times and Badabout 3 years ago
Being KOL-Centric: More Meaningful Expert Engagementabout 3 years ago
A New Era of Influence: Embracing the KOL-DOL Dynamic in Healthcareabout 3 years ago
Food for Thought: Make Room for Multiple Opinionsabout 3 years ago
The Pivot to Digitalabout 3 years ago
More than Ever, Data Will Dictate Future Fortunesabout 3 years ago
Generative AI’s Breakthrough Potential in Pharma Marketingabout 3 years ago
The Challenge of Taking on Falsified Medicines in EuropeNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics
2
President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs
3
Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff
4
Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer
5

